Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    17452677 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Condition: Pancreatic Cancer
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774)
2 Terminated Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Condition: Adenocarcinoma
Intervention: Drug: Zoledronic acid
3 Terminated Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine;   Biological: LAG-3
4 Completed Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride

Indicates status has not been verified in more than two years